🎉 Exciting news!
#Neuroprotection has received its first Journal Impact Factor: 4.1
A sincere thank you to our authors, reviewers, editors, editorial board members, and readers for making this milestone possible
Together, we are advancing neuroprotection from bench to bedside
When Every Minute Matters — New Insights Into Time-Dependent Characteristics of Thrombolytic Agents
In this #BloggingStroke post, @Sarah_Syed78 discusses #Stroke article by Wang & Yang et al. https://t.co/n3sElafq67
Celebrating 50 years of translational neuroscience in Kuopio!
In a #Neuroprotection Editorial, Jukka Jolkkonen highlights advances in microglia research, epilepsy gene therapy, stroke across the lifespan, human brain tissue studies and dementia prevention https://t.co/V3mzABBXop
How may chronic high-altitude exposure worsen intracerebral hemorrhage?
A new #Neuroprotection Review explores vascular–immune–neuronal dysfunction, hypoxia-inducible factor signaling, oxidative stress & neuroinflammation in this context.
https://t.co/UGKNQEepzq
🧠 Can efgartigimod help treat autoimmune encephalitis?
In a prospective study of 18 patients with anti-NMDAR or anti-LGI1 encephalitis, clinical scores improved & treatment was well tolerated. PET/MRI findings were promising in a subset #neuroprotection
https://t.co/V6C8401vCS
🧠 Could antimicrobial drugs be repurposed for #neuroprotection?
A new Neuroprotection Review explores how tetracyclines, macrolides, antimalarials & other agents may modulate neuroinflammation, oxidative stress and the gut-brain axis.
https://t.co/ZY3xnlLHLJ
Can #neuromodulation protect the brain after ischemic #stroke?
A #Neuroprotection systematic review & meta-analysis of 30 animal studies (2,347 reported animals) found reduced infarct volume and improved neurological outcomes.
https://t.co/7MDdN5UN69
How will China’s ischemic #stroke burden change by 2050?
A new study using GBD 2021 data projects continued growth in incidence, with population aging becoming the dominant driver. By 2050: 3.68M incident cases & 1.50M deaths projected.
https://t.co/GRqpQL7HOq
#Neuroprotection
🧠 Our latest Editorial by Piotr Walczak, Shen Li, Xunming Ji & Johannes Boltze explores the diverse contributions in Vol. 4, Issue 3 - from stroke, epilepsy & AD to TBI, #neuroregeneration, cell tracking & the history of glial biology.
https://t.co/ACdhdDzng9
#Neuroprotection
This review examines PFT-guided treatment, addressing both inadequate platelet inhibition and bleeding risk, and discusses future strategies for treatment intensification or de-escalation.
Can platelet function testing improve personalized antiplatelet therapy after cerebral infarction? [1/2]
https://t.co/MTlw1Ebg6V
#Neuroprotection#Stroke
Could serum elements help identify #Alzheimer’s disease?
This new article combines profiles of 20 serum elements with machine learning. A random forest model achieved 88% accuracy for AD identification, with exploratory prediction of MMSE & MoCA scores.
https://t.co/BSRPq5ExnZ
How is the global burden of #epilepsy changing?
Our latest review examines GBD 2021 data, highlighting epidemiological transitions, major regional & urban-rural inequalities, healthcare gaps, & priorities for integrated epilepsy governance.
https://t.co/3MGQoPRZMd
How limb laterality might impact Remote Ischemic Conditioning (RIC) in stroke. Practical clinical choices (which arm to use?) may actually have biological rationale via somatosensory modulation. Preclinical & clinical research must catch up! 🧠🩺https://t.co/Y1lsR2csWB
His observations anticipated concepts central to modern #neuroscience including #neuroinflammation, glial metabolism, neurovascular interactions and #neuroprotection.
More than a century later, his legacy remains highly relevant.
#Glia
🧠 A forgotten architect of glial biology
A new Commentary in #Neuroprotection revisits the work of Nicolás Achúcarro (1880–1918), whose pioneering histological studies helped establish #glia as dynamic participants in brain pathology. [1/2]
📖 https://t.co/RdRCemNjfZ